Hemab Therapeutics Holdings Inc (COAG)

Finanzdaten der Hemab Therapeutics Holdings Inc-Aktie (COAG)

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2026-06-30	2026-03-31
Periodenlänge	3 Monate	3 Monate
	10.45%26.08	23.61
Selling, General, and Administrative	38.35%5.74	4.15
Research and Development	4.50%20.34	19.46
Operating Income/Loss	10.45%-26.08	-23.61
Income/Loss From Continuing Operations Before Tax	6.08%-24.05	-22.68
Income Tax Expense/Benefit	708.33%0.10	0.01
	6.45%-24.15	-22.69
Attributable To Parent	6.45%-24.15	-22.69
Basic Average Shares	3,083%30.11	0.95
Diluted Average Shares	3,083%30.11	0.95
Basic Earnings Per Share	96.66%-0.80	-23.98
Diluted Earnings Per Share	96.66%-0.80	-23.98